Compare KLA Corp. (KLAC) vs Stryker Corporation (SYK) Price & Performance

KLA Corporation (KLAC) trades at $196.72, showing slight daily weakness but maintaining a strong uptrend supported by bullish technical indicators and robust fundamentals. The company reported revenue of $12.16 billion in 2025 with a net income margin of 35.57%, and has consistently beaten earnings expectations in recent quarters. AI-driven demand is fueling growth, with a backlog of $12.57 billion highlighting strong future revenue visibility.

The outlook for KLAC remains positive, driven by semiconductor equipment demand from AI and advanced packaging. Key opportunities include market leadership in inspection and metrology, while risks involve competitive pressures from Applied Materials and ASML, and execution challenges in scaling operations. The consensus price target of $223.88 suggests significant upside potential from current levels.

Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.

The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.